化学
药效团
磷酸二酯酶
环磷酸腺苷
肺病
环核苷酸
药理学
计算生物学
酶
生物化学
核苷酸
医学
内科学
受体
生物
基因
作者
Ting Peng,Baokun Qi,Jiang He,Hengming Ke,Jianyou Shi
标识
DOI:10.1021/acs.jmedchem.9b02170
摘要
Cyclic nucleotide phosphodiesterase 4 (PDE4) specifically hydrolyzes cyclic adenosine monophosphate (cAMP) and plays vital roles in biological processes such as cancer development. To date, PDE4 inhibitors have been widely studied as therapeutics for the treatment of various diseases such as chronic obstructive pulmonary disease, and many of them have progressed to clinical trials or have been approved as drugs. Herein, we review the advances in the development of PDE4 inhibitors in the past decade and will focus on their pharmacophores, PDE4 subfamily selectivity, and therapeutic potential. Hopefully, this analysis will lead to a strategy for development of novel therapeutics targeting PDE4.
科研通智能强力驱动
Strongly Powered by AbleSci AI